Summary of Apyx Medical Conference Call Company Overview - **Company**: Apyx Medical - **CEO**: Charlie Goodwin - **Focus**: Surgical aesthetics, specifically through the introduction of AYON technology Key Points Product Development and Market Position - Apyx Medical has developed AYON, a revolutionary integrated system for surgical aesthetics, which received approval in May and began commercial shipping in September [6][8] - AYON is designed to streamline surgical procedures by integrating multiple technologies into one system, allowing surgeons to perform various tasks simultaneously [7][22] - The company aims to dominate the surgical aesthetics market, positioning AYON as a game changer compared to existing technologies like VASER, which has seen no significant innovation in over a decade [5][6] Market Dynamics and Growth Potential - The introduction of GLP-1 drugs has significantly impacted the aesthetics market, leading to increased demand for surgical interventions due to skin laxity from rapid weight loss [16][19] - The market for GLP-1 drugs is projected to grow tenfold by 2030, creating a substantial opportunity for companies like Apyx Medical that can address the resulting aesthetic needs [17][18] - Apyx Medical anticipates a growth rate of 17%-19% for the aesthetics market, with a reported 38% growth in the surgical aesthetics market in Q4, and nearly 50% growth in the U.S. [49] Sales and Customer Engagement - Approximately 80% of AYON sales have come from existing customers upgrading from previous technologies, while 20% are new customers [42] - The list price for AYON is set at $360,000, which is seen as a competitive value proposition compared to the previous Apyx One generator priced at $165,000 [40][41] - The company is actively engaging with top body contouring doctors globally, expanding its customer base significantly [41] Financial Performance - Apyx Medical has reduced operating expenses from $53.8 million three years ago to $39.5 million this year, achieving EBITDA positivity and near break-even on an operating basis in the last quarter [76][79] - The company is on track to achieve cash flow positivity by the end of the year, driven by the successful launch of AYON and efficient cost management [75][79] International Expansion - Apyx Medical is currently selling Renuvion standalone in over 80 countries, with recent registrations in China and Korea, where the aesthetic market is expected to grow [52][61] - The company plans to introduce AYON internationally once it is registered in those markets, leveraging the growing demand for aesthetic procedures [50][52] Competitive Landscape - The aesthetics market is undergoing disruption due to GLP-1 drugs, which may negatively impact companies not aligned with the new patient needs, while benefiting those like Apyx Medical that can adapt [19][20] - Apyx Medical's integrated approach with AYON is expected to attract surgeons looking for efficiency and effectiveness in their practices [22][23] Additional Insights - The company emphasizes the importance of a strong sales force, with a focus on attracting high-caliber talent from the aesthetic space to drive sales of AYON [63][65] - AYON's design allows for a more organized and efficient operating room setup, which is particularly beneficial in smaller surgical environments [22][23] This summary encapsulates the key insights from the Apyx Medical conference call, highlighting the company's innovative product offerings, market dynamics, financial performance, and strategic growth plans.

Management View - Apyx Medical Corporation reported a record revenue of $19.2 million for Q4 2025, marking a significant achievement for the company [2] - The revenue growth was primarily driven by a 38% increase in surgical aesthetics product sales, which reached $16.7 million, largely attributed to the launch of the AYON body contouring product [2] Future Outlook - Apyx Medical has set a revenue growth target of 9%–11% for 2026, indicating confidence in the continued acceleration of the AYON product line [2]

Financial Data and Key Metrics Changes - The company reported record revenue of $19.2 million for Q4 2025, a 35% increase from $14.2 million in the same period last year [6][25] - Gross profit for Q4 2025 increased to $12 million compared to $9 million in the prior year, while gross profit margin slightly decreased to 62.6% from 63% [29] - Net loss attributable to stockholders was $1.3 million or $0.03 per share for Q4 2025, compared to a net loss of $4.6 million or $0.12 per share in the prior year [31] Business Line Data and Key Metrics Changes - Revenue for the surgical aesthetics segment increased 38% to $16.7 million in Q4 2025, driven by sales of the AYON body contouring system [26][27] - OEM segment sales increased 16% to $2.5 million in Q4 2025, attributed to increased sales volume to existing customers [28] Market Data and Key Metrics Changes - Domestic revenue increased 42% year-over-year to $15 million, while international revenue increased 15% year-over-year to $4.2 million [28] - The market for aesthetic surgery is evolving, with a notable increase in demand driven by the adoption of GLP-1 drugs for weight loss, leading to increased interest in body contouring treatments [16][18] Company Strategy and Development Direction - The company is focused on expanding the AYON platform and enhancing its market position by acquiring high-caliber sales talent [21][65] - Plans to submit for regulatory approvals in key international markets, including Europe and Brazil, are underway to expand AYON's reach [71] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong market demand for AYON and the potential for significant growth in the aesthetic surgery market [9][20] - The company anticipates total revenue for 2026 to be in the range of $57.5 million to $58.5 million, reflecting a 9%-11% increase compared to 2025 [35] Other Important Information - Cash used in operating activities decreased to $2.5 million in Q4 2025 from $2.9 million in the prior year, and for the full year, cash used decreased to $8 million from $18.7 million [32][33] - The company expects to achieve cash flow positivity no later than Q4 2026 [80] Q&A Session Summary Question: Can you provide more details on handpiece and capital equipment sales? - Management indicated that growth in Q4 was driven by AYON, with domestic sales growing nearly 50% [47] Question: What is the pricing strategy for AYON? - The list price for AYON is approximately $360,000, which includes the Apyx One generator and complementary components [50] Question: What feedback have you received from customers regarding AYON? - Customers have expressed strong satisfaction with AYON, with requests for the power-assisted handpiece expected in the first half of the year [54] Question: How are new salespeople being integrated into the company? - The company is leveraging the strength of AYON to attract top sales talent and is focusing on expanding market share [62][65] Question: What are the plans for AYON's international expansion? - Currently approved only in the U.S., the company plans to register AYON in key international markets, including Europe and Brazil [71]

Core Insights - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article emphasizes that users may be blocked from proceeding if an ad-blocker is enabled [1]

Core Viewpoint - Apyx Medical positions itself as a leader in the surgical aesthetics market, emphasizing the unique benefits of surgical aesthetics in providing durable and transformational results [4]. Group 1: Company Overview - Apyx Medical is hosting a virtual KOL event to discuss the commercial launch of its product AYON [3]. - The event features Dr. Vanek, who will share his experiences with AYON, indicating the company's focus on expert insights [2]. Group 2: Product Launch - The majority of the event will be dedicated to discussing the commercial launch of AYON, highlighting its significance in the company's strategy [3].

Group 1 - Apyx Medical is positioning itself as a leader in the surgical aesthetics market, emphasizing that surgical aesthetics provide durable and transformational results for patients [4] - The company is launching a new product, AYON, which will be a focal point of the event [3] - The market dynamics have been notably influenced by the introduction of GLP-1 drugs for weight loss, which has changed the landscape of surgical aesthetics [4] Group 2 - The event features Dr. Vanek as a key opinion leader (KOL), who will share his experiences with the AYON product [2][3] - The agenda includes an introduction by the CEO, a discussion on the commercial launch of AYON, and a Q&A session at the end [3]